More than 50 memory clinics across the United Kingdom are now offering simple blood tests to detect dementia, as two major research teams launch a five-year trial that could transform how the country diagnoses Alzheimer’s and related conditions. The trials, led by teams from the University of Oxford and University College London, will reach about 5,000 people worried about their memory — and could reshape a diagnostic system that currently leaves more than one in three people with dementia without a formal diagnosis.
- More than 50 U.K. memory clinics are participating in the five-year trial, offering blood tests to approximately 5,000 volunteers.
- Dementia is now the leading cause of death in Britain, with about 1 million people currently living with the condition and that number expected to reach 1.7 million by 2040.
- The trials are funded by Alzheimer’s Research UK and the Alzheimer’s Society, backed by £5 million from the People’s Postcode Lottery.
Why the U.K. dementia blood test trial matters
Getting a formal dementia diagnosis in the U.K. today is slow, difficult, and often painful. Current methods rely on mental ability tests, brain scans, or lumbar punctures — procedures where cerebrospinal fluid is drawn from the lower back. Patients and their families can wait up to four years just to receive an appointment and results, according to dementia charities.
The new blood tests work by detecting proteins associated with early-stage dementia and cognitive decline. They are far cheaper and simpler than existing diagnostic tools. Researchers hope that if the tests perform as well in real-world clinics as they have in research settings, they could dramatically speed up diagnoses and expand access to new treatments.
Fiona Carragher, director of research and influencing at the Alzheimer’s Society, said the current reliance on specialized tests has caused “unnecessary delays, worry and uncertainty” that prevent people from getting care early. She noted that only 2% of people with dementia can currently access the specialized tests needed to qualify for new treatments.
How the dementia blood tests will work across two trials
The first trial, led by Jonathan Schott, chief medical officer at Alzheimer’s Research UK, will focus on the most promising blood biomarker identified so far. It will enroll about 1,100 people at clinics across the country. The second and larger trial will test for multiple forms of dementia simultaneously, including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies, reaching about 4,000 participants.
Together, the trials will help determine whether these blood tests can be rolled out routinely through the National Health Service. Dr. Sheona Scales, director of research at Alzheimer’s Research UK, called dementia “the greatest health challenge facing the U.K.” and said the trials represent a critical step toward bringing advanced diagnostic tools within reach of everyday patients.
In 2022 alone, dementia claimed the lives of 66,000 people in England and Wales, with Alzheimer’s disease accounting for roughly two-thirds of all cases. Early diagnosis is not just about peace of mind — it is becoming a medical necessity, as several new Alzheimer’s drugs that are now entering clinical use require early-stage detection to be effective.
What a faster diagnosis could mean for patients
For people living with dementia and their families, a faster diagnosis can mean earlier access to support, care planning, and emerging treatments. Under the current system, the gap between concern and confirmed diagnosis stretches on for years, during which time the condition progresses and treatment windows narrow. A simple blood test, administered at a local memory clinic, could close that gap significantly.
The five-year trial timeline means results that could inform NHS policy may arrive well before the decade is out. If the data supports a national rollout, the U.K. would become one of the first countries to offer routine dementia blood testing through a public health system — a shift that could ripple outward and influence diagnostic standards globally.
Progress worth watching across health and prevention
This trial sits within a broader wave of advances in brain health research. Scientists recently found that an experimental drug cut Alzheimer’s risk in half in a landmark prevention trial, pointing to a future where early detection and early intervention work hand in hand. At the same time, the U.K.’s wider health picture is shifting in encouraging ways — cancer death rates in Britain recently fell to their lowest level on record, showing what sustained investment in research and early diagnosis can achieve. If you want to follow more stories like these, the Good News for Humankind archive tracks global milestones in health, climate, and justice every day. You can also sign up for the daily newsletter or explore how storytelling drives change through the Antihero Project.
Sourcing
This story was generated by AI based on a template created by Peter Schulte. It was originally reported by The Guardian.
More Good News
-
Mexico launches universal healthcare for all 133 million citizens
Mexico has officially launched a universal healthcare system covering all 133 million citizens through IMSS-Bienestar. The program offers free consultations, medicines, and hospital services regardless of employment or income — a historic shift that could reshape health equity across Latin America, though significant implementation challenges remain.
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana has declared its first marine protected area near Cape Three Points, targeting fish stocks decimated by decades of overfishing. The Ghana marine protected area marks a historic shift for a nation where millions depend on the sea for food and income — and could signal broader change across the Gulf of Guinea.
